Seer Proteograph Enables Unprecedented Genetic Marker Mapping For Proteogenomics Studies To Advance Drug And Biomarker Discovery
Portfolio Pulse from Benzinga Newsdesk
Seer, Inc. (NASDAQ:SEER) announced a study published in Nature Communications, led by Weill Cornell Medicine, showcasing the capabilities of Seer's Proteograph workflow in proteogenomics. The study, which utilized Seer's Proteograph Assay, identified over 18,000 peptides from around 3,000 proteins in blood samples, revealing 184 protein-altering variants in 137 genes. This breakthrough enables unprecedented mapping of genetic markers for drug and biomarker discovery, overcoming limitations of traditional affinity-based methods. Seer's Proteograph XT Assay Kit further enhances this by doubling throughput and maintaining high-resolution insights, supporting large-scale proteogenomic studies and precision medicine.
February 06, 2024 | 1:10 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Seer, Inc.'s Proteograph workflow demonstrated significant potential in proteogenomics, identifying numerous peptides and protein-altering variants, which could revolutionize drug and biomarker discovery. The launch of the Proteograph XT Assay Kit, enhancing throughput and resolution, positions Seer at the forefront of proteomics research.
The publication in Nature Communications and the launch of the Proteograph XT Assay Kit highlight Seer's innovative approach to proteogenomics, potentially leading to significant advancements in drug and biomarker discovery. This positions Seer as a leader in the field, likely attracting interest from the scientific community and investors, positively impacting its stock price in the short term.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100